Leveraging Technology to Cut Through the REMS Confusion

The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.

Download White Paper

You may also like:

Blog Post

It is one of the most talked about issues in healthcare. The population of the United States (and the world!) is aging. In 2010, 40 million Americans were age 65 and older, and that number is projected to swell to 88 million by 20...

View Blog Post
Blog Post

Two independent studies show that there is very little bleeding risk in patients undergoing dental surgery who are medicated with the new anticoagulants and that dose omission before or after dental surgery is not necessary. “Ne...

View Blog Post
Blog Post

Many pharmacies are exploring the issue of accreditation. They wonder: What will it take? Will it be worth the time, effort, and investment? These are valid questions, and we’ll attempt to answer them here. Wh...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up